natgillin/translations-raw huggingface dataset:
Alogliptin was not genotoxic in a standard battery of in vitro and in vivo genotoxicity studies. 
Alogliptin nije bio genotoksičan u standardnom setu in vitro i in vivo ispitivanja genotoksičnosti.
Administration of 25 mg alogliptin to patients with type 2 diabetes mellitus produced peak inhibition of DPP-4 within 1 to 2 hours and exceeded 93% both after a single 25 mg dose and after 14 days of once-daily dosing. 
Primjenom 25 mg alogliptina u bolesnika sa šećernom bolešću tipa 2 postignut je maksimum inhibicije DPP-4 unutar 1 do 2 sata koji prelazi 93% i nakon jednokratne doze od 25 mg i nakon 14 dana uzastopne primjene jedanput na dan.
In the cardiovascular outcomes study the rates of pancreatitis reports in patients treated with alogliptin or placebo were 3 or 2 events per 1,000 patient years, respectively. 
U ispitivanju kardiovaskularnih ishoda stope prijavljenih pankreatitisa u bolesnika liječenih alogliptinom ili placebom bile su 3 odnosno 2 događaja na 1000 bolesnik godina.
Alogliptin was not teratogenic in rats or rabbits with a systemic exposure at the NOAELs far above the human exposure at the recommended dose. 
Alogliptin nije bio teratogen u štakora ili kunića pri sistemskoj izloženosti na razini bez opaženih nuspojava koja je daleko iznad izloženosti kod ljudi pri preporučenoj dozi.
Hypersensitivity to the active substances or to any of the excipients listed in section 6.1 or history of a serious hypersensitivity reaction, including anaphylactic reaction, anaphylactic shock, and angioedema, to any dipeptidyl-peptidase-4 (DPP-4) inhibitor (see sections 4.4 and 4.8) 
• Preosjetljivost na djelatne tvari ili bilo koju od pomoćnih tvari navedenih u dijelu 6.1 ili ozbiljne reakcije preosjetljivosti u anamnezi, uključujući anafilaktičku reakciju, anafilaktički šok i angioedem, na bilo koji drugi inhibitor dipeptidil-peptidaze-4 (DPP-4) (vidjeti dijelove
Nylon/aluminium/polyvinyl chloride (PVC) blisters with push through aluminium lidding foil. 
Blisteri od najlon/aluminij/polivinil klorida (PVC) sa protisnom aluminijskom folijom.
Heart failure has been reported rarely with marketing use of pioglitazone, but more frequently when pioglitazone was used in combination with insulin or in patients with a history of cardiac failure. 
Zatajenje srca bilo je rijetko prijavljeno nakon stavljanja pioglitazona u promet, ali češće kad se pioglitazon primjenjivao u kombinaciji s inzulinom ili u bolesnika sa zatajenjem srca u anamnezi.
Intrinsic clearance is, therefore, reduced coupled with a higher unbound fraction of pioglitazone (see section 4.2). 
Intrinzički klirens je stoga smanjen, zajedno s većim udjelom nevezanog pioglitazona (vidjeti dio 4.2).
The improved glycaemic control is associated with a reduction in both fasting and postprandial plasma insulin concentrations. 
Poboljšana kontrola glikemije povezana je sa smanjenjem koncentracija inzulina u plazmi natašte i nakon obroka.
In studies in vitro, alogliptin was found to be neither a substrate nor an inhibitor of key transporters associated with disposition of the active substance in the kidney: organic anion transporter-1, organic anion transporter-3 or organic cationic transporter-2 (OCT2). 
U in vitro ispitivanjima nađeno je da alogliptin nije supstrat ni inhibitor ključnih transportera povezanih s dispozicijom lijeka u bubrezima: transportera organskih aniona-1 (OAT-1), transportera organskih aniona-3 (OAT-3) ili transportera organskih kationa-2 (OCT2).
Post marketing cases of peripheral oedema and cardiac failure have also been reported in patients with concomitant use of pioglitazone and nonsteroidal anti-inflammatory drugs (NSAIDs), including selective COX-2 inhibitors. 
U razdoblju nakon stavljanja lijeka u promet također su prijavljeni slučajevi perifernog edema i zatajenja srca u bolesnika koji su istodobno uzimali pioglitazon i nesteroidne protuupalne lijekove, uključujući selektivne COX-2 inhibitore.
Post-marketing spontaneous reports of hypersensitivity reactions in patients treated with pioglitazone include anaphylaxis, angioedema, and urticaria. 
Spontano prijavljene reakcije preosjetljivosti u bolesnika liječenih pioglitazonom nakon stavljanja lijeka u promet uključuju anafilaksiju, angioedem i urtikariju.
In clinical studies, alogliptin had no clinically relevant effect on the pharmacokinetics of caffeine, (R)-warfarin, pioglitazone, glyburide, tolbutamide, (S)-warfarin, dextromethorphan, atorvastatin, midazolam, an oral contraceptive (norethindrone and ethinyl oestradiol), digoxin, fexofenadine, metformin, or cimetidine, thus providing in vivo evidence of a low propensity to cause interaction with substrates of CYP1A2, CYP3A4, CYP2D6, CYP2C9, p-glycoprotein, and OCT2. 
U kliničkim ispitivanjima alogliptin nije imao klinički značajan učinak na farmakokinetiku kofeina, (R)-varfarina, pioglitazona, gliburida, tolbutamida, (S)-varfarina, dekstrometorfana, atorvastatina, midazolama, oralnog kontraceptiva (noretindron i etinil estradiol), digoksina, feksofenadina, metformina ili cimetidina, potvrđujući i in vivo dokaz niskog potencijala interakcija sa supstratima CYP1A2, CYP3A4, CYP2D6, CYP2C9, p-glikoproteina i OCT2.
In studies performed with the individual active substances, both alogliptin and pioglitazone were excreted in the milk of lactating rats. 
U ispitivanjima pojedinačnih djelatnih tvari, i alogliptin i pioglitazon su se izlučivali u mlijeku štakorica u laktaciji.
Studies in vitro have shown alogliptin to be a mild inducer of CYP3A4, but alogliptin has not been shown to induce CYP3A4 in studies in vivo. 
Ispitivanja in vitro su pokazala da je alogliptin blagi induktor CYP3A4, međutim ispitivanja in vivo nisu pokazala da alogliptin inducira CYP3A4.
In a 20-week study, as well as reducing fasting triglycerides, pioglitazone reduced postprandial hypertriglyceridaemia through an effect on both absorbed and hepatically synthesised triglycerides. 
U ispitivanju u trajanju od 20 tjedana, osim što je snizio trigliceride natašte, pioglitazon je snizio postprandijalnu hipertrigliceridemiju tako što je utjecao na apsorbirane trigliceride i na one sintetizirane u jetri.
A clinical study of alogliptin as add-on therapy to pioglitazone demonstrated that there was no clinically relevant increase in hypoglycaemia rate compared to placebo. 
U kliničkim ispitivanjima alogliptina kao dodatka terapiji pioglitazonom nije bilo klinički značajnog povećanja stope hipoglikemije u usporedbi s placebom.
The decision whether to continue the patient on therapy with Incresync should be guided by clinical judgement pending laboratory evaluations. 
Odluku o nastavku terapije Incresyncom treba donijeti na temelju kliničke procjene ovisno o laboratorijskim nalazima.
In clinical studies of up to two years duration, pioglitazone reduced total plasma triglycerides and free fatty acids, and increased HDL-cholesterol levels compared to placebo, metformin or gliclazide. 
U kliničkim ispitivanjima u trajanju do dvije godine, pioglitazon je snizio ukupne trigliceride u plazmi i slobodne masne kiseline te povisio razine HDL-kolesterola u usporedbi s placebom, metforminom i gliklazidom.
No studies in lactating animals have been conducted with the combined active substances of Incresync. 
Nisu provedena ispitivanja na životinjama u laktaciji s kombiniranim djelatnim tvarima Incresynca.
In most clinical studies, reduced total plasma triglycerides and free fatty acids, and increased HDL-cholesterol levels were observed as compared to placebo with small, but not clinically significant, increases in LDL-cholesterol levels. 
U većini kliničkih ispitivanja primijećeno je sniženje ukupnih triglicerida i slobodnih masnih kiselina u plazmi te povišenje razine HDL-kolesterola u usporedbi s placebom, uz mala ali ne i klinički značajna povišenja razina LDL-kolesterola.
Following administration of an oral dose of [14C] alogliptin, 76% of total radioactivity was eliminated in the urine and 13% was recovered in the faeces. 
C] alogliptina, 76% ukupne radioaktivnosti eliminirano je mokraćom, a 13% stolicom.
Tlf: +47 6676 3030 infonorge@takeda.com 
Tlf: +47 6676 3030 infonorge@nycomed.no
In combination studies, pioglitazone added to metformin resulted in mean weight increase over one year of 1.5 kg and added to a sulphonylurea of 2.8 kg. 
Dodavanje pioglitazona metforminu u ispitivanjima kombinacija rezultiralo je povećanjem srednje vrijednosti težine tijekom jedne godine za 1,5 kg, a dodavanje sulfonilureji za 2,8 kg.
What Incresync is used for 
Za što se Incresync koristi
No environmental impact is anticipated from the clinical use of pioglitazone. 
Ne očekuje se utjecaj na okoliš tijekom kliničke primjene pioglitazona.
Fractures were observed in 2.6% of women taking pioglitazone compared to 1.7% of women treated with a comparator. 
Prijelomi su opaženi u 2,6% žena koje su uzimale pioglitazon u usporedbi sa 1,7% žena liječenih usporednim lijekom.
When the 4-hour postprandial glucose concentrations were averaged across breakfast, lunch and dinner, 14 days of treatment with 25 mg alogliptin resulted in a mean placebo-corrected reduction from baseline of -35.2 mg/dL. 
Ako se koncentracije glukoze 4 sata nakon obroka preračunaju na prosječnu vrijednost doručka, ručka i večere, 14 dana liječenja s 25 mg alogliptina dovodi do srednje vrijednosti sniženja razine glukoze koja nakon korekcije na temelju placeba iznosi -35,2 mg/dl u odnosu na početnu vrijednost.
Studies in animal models of diabetes showed that concomitant treatment with alogliptin and pioglitazone produced both additive and synergistic improvements in glycaemic control, increased pancreatic insulin content and normalised pancreatic beta-cell distribution. 
Ispitivanja šećerne bolesti na životinjskim modelima pokazala su da istodobno liječenje alogliptinom i pioglitazonom dodatno i sinergistički poboljšava kontrolu glikemije, povisuje sadržaj inzulina u gušterači i normalizira distribuciju beta-stanica u gušterači.
In clinical studies with pioglitazone, the incidence of elevations of ALT greater than three times the upper limit of normal was equal to placebo but less than that seen in metformin or sulphonylurea comparator groups. 
U kliničkim ispitivanjima pioglitazona, incidencija povišenja ALT-a za više od tri puta iznad gornje granice normale bila je jednaka onoj za placebo, ali manja od one viđene u skupinama koje su kao usporedni lijek primale metformin ili sulfonilureju.
Due to its pioglitazone component, Incresync should not be used in patients with hepatic impairment (see section 4.2). 
Zbog sadržanog pioglitazona, Incresync se ne smije primjenjivati u bolesnika s oštećenjem jetre (vidjeti dio 4.2).
Adults (≥ 18 years old) The dose should be individualised on the basis of the patient's current treatment regimen 
Dozu Incresynca treba individualno odrediti na temelju trenutnog režima liječenja svakog bolesnika.
In comparator groups, addition of sulphonylurea to metformin resulted in a mean weight gain of 1.3 kg and addition of metformin to a sulphonylurea a mean weight loss of 1.0 kg. 
U skupinama koje su primale usporedni lijek, dodavanje sulfonilureje metforminu rezultiralo je povećanjem srednje vrijednosti težine za 1,3 kg, a dodavanje metformina sulfonilureji smanjenjem težine za 1,0 kg.
Administration with a high-fat meal resulted in no change in total and peak exposure to alogliptin. 
Primjenom uz obrok s visokim sadržajem masti nije bilo promjene u ukupnoj i vršnoj izloženosti alogliptinu.
This was determined by clinically relevant and statistically significant reductions in glycosylated haemoglobin (HbA1c) and fasting plasma glucose compared to control from baseline to study endpoint. 
To je potvrđeno klinički i statistički značajnim sniženjima glikoziliranog hemoglobina (HbA1c) i glukoze u plazmi natašte u usporedbi s kontrolnom skupinom od početne vrijednosti do ishoda ispitivanja.
If you take more tablets than you should, or if someone else or a child takes your medicine, contact or go to your nearest emergency centre straight away. 
Ako uzmete više tableta nego što ste trebali, ili ako netko drugi ili dijete uzme
Neoplasms benign, malignant and unspecified (including cysts and polyps) bladder cancer uncommon 
Dobroćudne, zloćudne i nespecificirane novotvorine (uključujući ciste i polipe)
At baseline, patients had a mean age of 61 years, mean duration of diabetes of 9.2 years, and mean HbA1c of 8.0%. 
Pri uključivanju u ispitivanje bolesnici su imali u prosjeku 61 godinu, prosječno trajanje dijabetesa 9,2 godina i prosječni HbA1c od 8,0%.
Results from clinical interaction studies also demonstrate that there are no clinically relevant effects of gemfibrozil (a CYP2C8/9 inhibitor), fluconazole (a CYP2C9 inhibitor), ketoconazole (a CYP3A4 inhibitor), cyclosporine (a p-glycoprotein inhibitor), voglibose (an alpha-glucosidase inhibitor), digoxin, metformin, cimetidine, pioglitazone or atorvastatin on the pharmacokinetics of alogliptin. 
Rezultati kliničkih ispitivanja interakcija također pokazuju da nema klinički značajnih učinaka gemfibrozila (inhibitor CYP2C8/9), flukonazola (inhibitor CYP2C9), ketokonazola (inhibitor CYP3A4), ciklosporina (inhibitor p-glikoproteina), vogliboze (inhibitore alfa-glukozidaze), digoksina, metformina, cimetidina, pioglitazona ili atrovastatina na farmakokinetiku alogliptina.
No dose adjustment is necessary (see section 4.2). 
Prilagodba doze nije potrebna (vidjeti dio 4.2).
Swallow your tablet(s) whole with water. 
Tabletu progutajte cijelu s vodom.
Interaction studies have shown that pioglitazone has no relevant effect on either the pharmacokinetics or pharmacodynamics of digoxin, warfarin, phenprocoumon or metformin. 
Ispitivanja interakcija pokazala su da pioglitazon nema značajnog učinka na farmakokinetiku niti na farmakodinamiku digoksina, varfarina, fenprokumona i metformina.
In a pooled analysis of the data from 12 studies, the overall incidence of any episode of hypoglycaemia was similar in patients ≥ 65 years old treated with 25 mg alogliptin (3.8%) to that in patients < 65 years old (3.6%). 
U analizi objedinjenih podataka iz 12 ispitivanja, ukupna incidencija svih epizoda hipoglikemije bila je u bolesnika u dobi od ≥ 65 godina starosti liječenih s 25 mg alogliptina (3,8%) slična kao i u onih < 65 godina starosti (3,6%).
If you forget to take a dose, take it as soon as you remember it. Do not take a double dose to make up for a forgotten dose. 
Nemojte uzeti dvostruku dozu kako biste nadoknadili zaboravljenu dozu.
Incresync should not be used in patients with type 1 diabetes mellitus. 
Incresync se ne smije primjenjivati u bolesnika sa šećernom bolešću tipa
Symptoms may include: trembling, sweating, anxiety, blurred vision, tingling lips, paleness, 
Simptomi mogu uključivati: drhtavicu, znojenje, tjeskobu, zamućen vid, trnce u usnicama,
Film-coating 
Film-ovojnica
Carnauba wax Glycerol mono-oleate Glycerol mono-oleate 
karnauba vosak karnauba vosak glicerolmonooleat glicerolmonooleat
The effect of pioglitazone (45 mg monotherapy vs. placebo) was studied in a small 18-week study in type 2 diabetics. 
Učinak pioglitazona (45 mg monoterapija naspram placeba) ispitivao se u malom ispitivanju u trajanju od 18 tjedana u bolesnika sa šećernom bolešću tipa
Incresync may, therefore, be administered with or without food. 
Incresync se stoga može primijeniti s hranom ili bez nje.
Pioglitazone was devoid of genotoxic potential in a comprehensive battery of in vivo and in vitro genotoxicity assays. 
Pioglitazon nije pokazao genotoksični potencijal u sveobuhvatnom setu testova genotoksičnosti in vivo i in vitro.
Caution should be exercised in patients with a history of pancreatitis. 
Nužan je oprez u bolesnika s pankreatitisom u anamnezi.
There may be an increased possibility of becoming pregnant because you may ovulate again when you take Incresync. 
Kad uzimate Incresync možete ponovno imati ovulaciju pa mogućnost trudnoće može biti povećana.
No adverse effects of alogliptin were observed upon fertility, reproductive performance, or early embryonic development in rats up to a systemic exposure far above the human exposure at the recommended dose. 
Nisu opažene nuspojave na plodnost, reprodukciju ili rani embrionalni razvoj štakora sve do sistemske izloženosti koja je daleko iznad izloženosti kod ljudi pri preporučenoj dozi.
No information is available on pioglitazone and alogliptin use in dialysed patients and, therefore, co-administered alogliptin plus pioglitazone should not be used in such patients (see sections 4.2 and 5.2). 
Budući da nema dostupnih informacija o primjeni pioglitazona i alogliptina kod bolesnika na dijalizi, kod njih se alogliptin i pioglitazon ne smiju primjenjivati istodobno. (vidjeti dijelove 4.2 i 5.2).
Table 3: Change in HbA1c (%) from baseline with alogliptin 25 mg by active-controlled study (PPS, LOCF) 
Tablica 6: Promjena HbA1c (%) od početne vrijednosti za alogliptin 25 mg u ispitivanju kontroliranom aktivnom kontrolom (PPS, LOCF)
Mean baseline HbA1c (%) (SD) 
Srednja početna vrijednost HbA1c (%) (SD)
Animal studies of up to 13-weeks duration have been conducted with the combined substances in Incresync. 
Kombinirane tvari sadržane u lijeku Incresync ispitane su u ispitivanjima na životinjama u trajanju od 13 tjedana.
In PROactive, a cardiovascular outcome study, 5,238 patients with type 2 diabetes mellitus and pre-existing major macrovascular disease were randomised to pioglitazone or placebo in addition to existing anti-diabetic and cardiovascular therapy, for up to 3.5 years. 
U PROactive ispitivanju kardiovaskularnih ishoda, 5238 bolesnika sa šećernom bolešću tipa 2 i već postojećom velikom makrovaskularnom bolešću bilo je randomizirano u skupinu koja je primala pioglitazon i onu koja je primala placebo uz postojeću antidijabetičku i kardiovaskularnu terapiju u trajanju do 3,5 godine.
It is recommended, therefore, that patients treated with Incresync undergo periodic monitoring of liver enzymes. 
Stoga se u bolesnika liječenih Incresyncom preporučuje povremeno pratiti jetrene enzime.
Incresync is not recommended for patients with severe renal impairment (CrCl < 30 mL/min) or end-stage renal disease requiring dialysis. 
Incresync se ne preporučuje bolesnicima s teškim oštećenjem bubrega (klirens kreatinina < 30 ml/min) ili završnim stadijem bolesti bubrega koji zahtijevaju dijalizu.
No adverse effects on fertility were observed in animal studies conducted with alogliptin (see section 5.3). 
U ispitivanjima na životinjama provedenim s alogliptinom nisu opažene nuspojave na plodnost (vidjeti dio 5.3).
There is no experience of using Incresync in pregnant women or during breast-feeding. 
Nema iskustava s primjenom lijeka Incresync u trudnica ili tijekom dojenja.
Fasting and postprandial glycaemic control is improved following treatment with pioglitazone in patients with type 2 diabetes mellitus. 
Poboljšava se kontrola glikemije natašte i nakon obroka nakon liječenja pioglitazonom u bolesnika sa šećernom bolešću tipa
There are no data from the use of Incresync in pregnant women. 
Nema podataka o primjeni Incresynca u trudnica.
In vitro studies suggest that alogliptin does not inhibit nor induce CYP 450 isoforms at concentrations achieved with the recommended dose of 25 mg alogliptin (see section 5.2). 
In vitro ispitivanja pokazuju da, u koncentracijama koje se postižu preporučenom dozom od 25 mg alogliptina ne inhibira niti inducira CYP 450 izoenzime (vidjeti dio 5.2).
As there is a need for dose adjustment of alogliptin in patients with moderate or severe renal impairment, or end-stage renal disease requiring dialysis, appropriate assessment of renal function is recommended prior to initiation of Incresync and periodically thereafter (see section 4.2). 
S obzirom na potrebu prilagodbe doze alogliptina u bolesnika s umjerenim ili teškim oštećenjem bubrega, ili završnim stadijem bolesti bubrega koji zahtijeva dijalizu, prije početka i povremeno tijekom liječenja Incresyncom potrebna je odgovarajuća procjena funkcije bubrega (vidjeti dio 4.2).
An increased incidence in bone fractures in women was seen in a pooled analysis of adverse reactions of bone fracture from randomised, controlled, double-blind clinical studies in over 8,100 pioglitazoneand 7,400 comparator-treated patients, on treatment for up to 3.5 years. 
Povećana incidencija prijeloma kostiju u žena opažena je u analizi objedinjenih podataka o prijelomima kostiju kao nuspojave u randomiziranim, kontroliranim, dvostruko slijepim kliničkim ispitivanjima na više od 8100 bolesnika liječenih pioglitazonom i 7400 bolesnika liječenih usporednim lijekom u trajanju do 3,5 godine.
Incresync is not recommended for patients with severe renal impairment or end-stage renal disease requiring dialysis (see section 4.2). 
Incresync se ne preporučuje bolesnicima sa teškim oštećenjem bubrega ili završnim stadijem bolesti bubrega koji zahtijeva dijalizu (vidjeti dio 4.2).
No dose adjustment is necessary based on age (see section 4.4). 
Nije potrebna prilagodba doze s obzirom na dob (vidjeti dio 4.4).
Treatment with pioglitazone has been shown to reduce hepatic glucose output and to increase peripheral glucose disposal in the case of insulin resistance. 
Pokazalo se da liječenje pioglitazonom smanjuje otpuštanje glukoze iz jetre i povećava perifernu dostupnost glukoze u slučaju inzulinske rezistencije.
See leaflet for further information. 
Time se omogućuje brzo otkrivanje novih sigurnosnih informacija.
In the 3.5 year PROactive study, 44/870 (5.1%) of pioglitazone-treated female patients experienced fractures compared to 23/905 (2.5%) of female patients treated with comparator. 
U PROactive ispitivanju u trajanju od 3,5 godine, 44/870 (5,1%) bolesnica liječenih pioglitazonom doživjelo je prijelome u usporedbi s 23/905 (2,5%; %) bolesnica liječenih usporednim lijekom.
In a pooled analysis of the data from 13 studies, the overall incidences of cardiovascular death, non fatal myocardial infarction and non-fatal stroke were comparable in patients treated with 25 mg alogliptin, active control or placebo. 
U analizi objedinjenih podataka iz 13 ispitivanja, ukupne incidencije kardiovaskularne smrti, infarkta miokarda bez smrtnog ishoda i moždanog udara bez smrtnog ishoda bile su usporedive u bolesnika liječenih s 25 mg alogliptina, aktivnom kontrolom ili placebom.
Table 2: Change in HbA1c (%) from baseline with alogliptin 25 mg at Week 26 by placebo-controlled study (FAS, LOCF) 
Tablica 5: Promjena HbA1c (%) od početne vrijednosti za alogliptin 25 mg u 26. tjednu u ispitivanju kontroliranom placebom (FAS, LOCF)
In vitro studies have shown no evidence that pioglitazone inhibits any subtype of cytochrome P450. 
In vitro ispitivanja nisu dokazala da pioglitazon inhibira bilo koji podtip citokroma P450.
For patients with moderate renal impairment (CrCl ≥ 30 to ≤ 50 mL/min), one-half of the recommended dose of alogliptin should be administered. 
Za bolesnike s umjerenim oštećenjem bubrega (klirens kreatinina ≥ 30 do ≤ 50 ml/min) potrebno je primijeniti polovicu preporučene doze alogliptina.
In the 3.5 year cardiovascular risk PROactive study, 44/870 (5.1%; 1.0 fractures per 100 patient years) of pioglitazone-treated female patients experienced fractures compared to 23/905 (2.5%; 0.5 fractures per 100 patient years) of female patients treated with comparator. 
U PROactive ispitivanju kardiovaskularnog rizika u trajanju od 3,5 godine, 44/870 (5,1%; 1,0 prijelom na 100 bolesnik-godina) bolesnica liječenih pioglitazonom imalo je prijelome u usporedbi s 23/905 (2,5%; 0,5 prijeloma na 100 bolesnik-godina) bolesnica liječenih usporednim lijekom.
Similar changes were seen in metformin- (haemoglobin 3-4% and haematocrit 3.6-4.1% relative reductions) and to a lesser extent sulphonylurea- and insulin- (haemoglobin 1-2% and haematocrit 1-3.2% relative reductions) treated patients in comparative-controlled studies with pioglitazone. 
U usporednim kontroliranim ispitivanjima pioglitazona slične su promjene opažene u bolesnika liječenih metforminom (relativno smanjenje hemoglobina za 3-4% i hematokrita za 3,6-4,1%) i u manjoj mjeri u bolesnika liječenih sulfonilurejom i inzulinom (relativno smanjenje hemoglobina za 1-2% i hematokrita za 1-3,2%).